Leighl, N. B. Et Al. 2024. Subcutaneous Versus Intravenous Amivantamab, Both in Combination with Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results from the Phase III PALOMA-3 Study. Journal of Clinical Oncology .

Leighl, N. B., Akamatsu, H., Lim, S. M., Cheng, Y., Minchom, A. R., Marmarelis, M. E., ... Sanborn, R. E.(2024). Subcutaneous Versus Intravenous Amivantamab, Both in Combination with Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results from the Phase III PALOMA-3 Study. Journal of Clinical Oncology .

Leighl, Natasha Et Al. "Subcutaneous Versus Intravenous Amivantamab, Both in Combination with Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results from the Phase III PALOMA-3 Study," Journal of Clinical Oncology , 2024

Leighl, Natasha B. Et Al. "Subcutaneous Versus Intravenous Amivantamab, Both in Combination with Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results from the Phase III PALOMA-3 Study." Journal of Clinical Oncology , 2024

Leighl, N. B. Et Al. (2024) . "Subcutaneous Versus Intravenous Amivantamab, Both in Combination with Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results from the Phase III PALOMA-3 Study." Journal of Clinical Oncology .

@article{article, author={Natasha B. Leighl Et Al. }, title={Subcutaneous Versus Intravenous Amivantamab, Both in Combination with Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results from the Phase III PALOMA-3 Study}, journal={Journal of Clinical Oncology}, year=2024}